ConductScience.org, home
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
API referenceFor AI assistants

Trial · NCT05635838

Participant flow24

How many started, completed or left each group, period by period.

1 to 20 of 24

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
16-Week DBVC PeriodSTARTEDDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID34
16-Week DBVC PeriodSTARTEDDBVC Period: Vehicle Cream BID35
16-Week DBVC PeriodSTARTEDOpen-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BID0
16-Week DBVC PeriodSTARTEDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID0
16-Week DBVC PeriodCOMPLETEDDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID24
16-Week DBVC PeriodCOMPLETEDDBVC Period: Vehicle Cream BID32
16-Week DBVC PeriodCOMPLETEDOpen-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BID0
16-Week DBVC PeriodCOMPLETEDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID0
16-Week DBVC PeriodNOT COMPLETEDDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID10
16-Week DBVC PeriodNOT COMPLETEDDBVC Period: Vehicle Cream BID3
16-Week DBVC PeriodNOT COMPLETEDOpen-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BID0
16-Week DBVC PeriodNOT COMPLETEDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID0
16-Week OLE PeriodSTARTEDDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID0
16-Week OLE PeriodSTARTEDDBVC Period: Vehicle Cream BID0
16-Week OLE PeriodSTARTEDOpen-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BID24
16-Week OLE PeriodSTARTEDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID32
16-Week OLE PeriodCOMPLETEDDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID0
16-Week OLE PeriodCOMPLETEDDBVC Period: Vehicle Cream BID0
16-Week OLE PeriodCOMPLETEDOpen-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BID21
16-Week OLE PeriodCOMPLETEDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID24

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05635838/flow

API referenceFor AI assistants